Compositions and methods for the treatment of congenital adrenal hyperplasia
Patent Information
- Application Number
- HK62026124903
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-04-09
- Filing Date
- 2026-06-16
- Publication Date
- 2026-09-11
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
The abstract provides compositions and methods for treating congenital adrenal hyperplasia (CAH).
Claims
CLAIMS1. A method of treating congenital adrenal hyperplasia (CAH) in a subject comprising administering to the subject a compound of Formula (I), or a pharmaceutically acceptable salt thereof:Formula (I).
2. A method of treating hyperandrogenism in a subject with CAH comprising administering to the subject a compound of Formula (I), or a pharmaceutically acceptable salt thereof:Formula (I).
3. The method of any one of claims 1-2, wherein the compound of Formula (I), or the pharmaceutically acceptable salt thereof, is administered in a therapeutically effective amount.
4. The method of any one of claims 1-3, wherein the compound of Formula (I), or the pharmaceutically acceptable salt thereof, is administered in an amount equivalent to about 40 mg to about 160 mg of Formula (I).
5. The method of any one of claims 1-3, wherein the compound of Formula (I), or the pharmaceutically acceptable salt thereof, is administered in an amount equivalent to about 80 mg to about 160 mg of Formula (I).
6. The method of any one of claims 1-3, wherein the compound of Formula (I), or the pharmaceutically acceptable salt thereof, is administered in an amount equivalent to about 80 mg to about 120 mg of Formula (I).
7. The method of any one of claims 1-3, wherein the compound of Formula (I), or the pharmaceutically acceptable salt thereof, is administered in an amount equivalent to about 40 mg of Formula (I).
8. The method of any one of claims 1-3, wherein the compound of Formula (I), or the pharmaceutically acceptable salt thereof, is administered in an amount equivalent to about 80 mg of Formula (I).
9. The method of any one of claims 1-3, wherein the compound of Formula (I), or the pharmaceutically acceptable salt thereof, is administered in an amount equivalent to about 120 mg of Formula (I).
10. The method of any one of claims 1-3, wherein the compound of Formula (I), or the pharmaceutically acceptable salt thereof, is administered in an amount equivalent to about 160 mg of Formula (I).
11. The method of any one of claims 1-10, wherein the compound of Formula (I), or the pharmaceutically acceptable salt thereof, is administered in one or more unit dosage forms.
12. The method of claim 11, wherein the unit dosage form comprises the compound of Formula (I), or the pharmaceutically acceptable salt thereof, in an amount of equivalent to about 40 mg of Formula (I).
13. The method of any one of claims 11-12, wherein the unit dosage form is an oral unit dosage form.
14. The method of any one of claims 1-13, wherein the compound of Formula (I), or the pharmaceutically acceptable salt thereof, is administered daily.
15. The method of any one of claims 1-13, wherein the compound of Formula (I), or the pharmaceutically acceptable salt thereof, is administered once daily.
16. The method of any one of claims 1-15, wherein the CAH is caused by 21 -hydroxylase deficiency.
17. The method of any one of claims 1-16 wherein the subject is concurrently on glucocorticoid replacement therapy.
18. The method of any one of claims 1-16, wherein the subject is concurrently on hydrocortisone, prednisolone, prednisone, or methylprednisolone therapy.
19. The method of any one of claims 1-16, wherein the subject is concurrently on mineralocorticoid replacement therapy.
20. The method of any one of claims 1-16, wherein the subject is concurrently on fludrocortisone therapy.
21. The method of any one of claims 1-20, wherein treating comprises reducing the subject’s serum levels of androstenedione (A4) from baseline.
22. The method of claim 21, wherein the subject’s serum levels of A4 are reduced by >75% from baseline.
23. The method of claim 21, wherein the subject’s serum levels of A4 are reduced by >80% from baseline.
24. The method of claim 21, wherein the subject’s serum levels of A4 are reduced by >85% from baseline.
25. The method of claim 21, wherein the subject’s serum levels of A4 are reduced by >90% from baseline.
26. The method of any one of claims 1-20, wherein treating comprises reducing the subject’s serum levels of 17-hydroxyprogesterone (17-OHP) from baseline.
27. The method of claim 26, wherein the subject’s serum levels of 17-OHP are reduced by >75% from baseline.
28. The method of claim 26, wherein the subject’s serum levels of 17-OHP are reduced by >80% from baseline.
29. The method of claim 26, wherein the subject’s serum levels of 17-OHP are reduced by >85% from baseline.
30. The method of claim 26, wherein the subject’s serum levels of 17-OHP are reduced by >90% from baseline.
31. The method of claim 26, wherein the subject’s serum levels of 17-OHP are reduced by >95% from baseline.
32. The method of any one of claims 1-20, wherein treating comprises reducing the subject’s serum levels of testosterone from baseline.
33. The method of claim 32, wherein the subject’s serum levels of testosterone are reduced by >50% from baseline.
34. The method of claim 32, wherein the subject’s serum levels of testosterone are reduced by >60% from baseline.
35. The method of claim 32, wherein the subject’s serum levels of testosterone are reduced by >70% from baseline.
36. The method of claim 32, wherein the subject’s serum levels of testosterone are reduced by >80% from baseline.
37. The method of any one of claims 32-36, wherein the subject is a female.
38. The method of any one of claims 1-37, wherein treating comprises reducing the subject’s serum levels of one or more of 11 -deoxycorticosterone (11-DOC), 1 ip- hydroxyandrostenedione (11-0HA4), 11 -ketoandrostenedione (l l-ketoA4), l ip- hydroxytestosterone (11-OHT), and 11 -ketotestosterone (11-ketoT) from baseline.
39. The method of any one of claims 21-36, wherein the baseline is measured in the morning.
40. The method of any one of claims 1-39, wherein treating comprises reducing adrenal gland size.
41. The method of any one of claims 1-39, wherein treating comprises reducing waist circumference.
42. The method of any one of claims 1-39, wherein treating comprises reducing levels of hemoglobin A1C (HbAlC).
43. The method of any one of claims 1 and 3-39, wherein the subject has hyperandrogeni sm .
44. The method of any one of claims 1-39, wherein the subject has acne.
45. The method of claim 44, wherein the subject reports their acne has improved following administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof.
46. The method of any one of claims 1-39, wherein the subject has hirsutism.
47. The method of claim 46, wherein the subject reports their hirsutism has improved following administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof.
48. The method of any one of claims 1-39, wherein the subject has menstrual dysfunction.
49. The method of claim 48, wherein the subject reports their menstrual dysfunction has improved following administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof.
50. The method of any one of claims 1-39, wherein the subject has testicular adrenal rests tumor (TART).
51. The method of claim 50, wherein the subject’s TART has improved following administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof.
52. A pharmaceutical composition for use in treating a subject with CAH, wherein the composition comprises a compound of Formula (I), or a pharmaceutically acceptable salt thereof:Formula (I).
53. Use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a subject with CAH:Formula (I).
54. A pharmaceutical composition for use in treating hyperandrogenism in a subject with CAH, wherein the composition comprises a compound of Formula (I), or a pharmaceutically acceptable salt thereof:Formula (I).
55. Use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating hyperandrogenism in a subject with CAH:Formula (I).
